Clinical Trial

A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic profile in the body after infusion of RS001 injection, and preliminary efficacy in subjects with CD19-positive relapsed/refractory B-cell malignancies (BCM).
Trial Details
NCT Number NCT06894693
Lead Sponsor Guangdong Ruishun Biotech Co., Ltd
Conditions B-cell Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia
Enrollment 13 participants
Start Date 2025-04-01
Primary Completion 2026-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-25